GlassScriptPhysician profile
Narin J Tipton
NPI 1477720654
$18,063.48
in general payments reported to CMS, 2019-2025
36 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,784 · 2022: $3,015 · 2023: $4,665 · 2024: $5,131 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,041.87 |
| Education | $222.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,945.44 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,609.82 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $1,783.79 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,642.94 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $979.31 | 2021-2025 | |
| Qol Medical, LLC | $815.94 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $791.03 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $626.08 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $587.94 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $568.22 | 2021-2024 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $552.53 | 2021-2025 | Ocaliva |
| Daiichi Sankyo INC. | $424.68 | 2021-2024 | Injectafer |
| Ardelyx, INC. | $412.61 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $352.30 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $326.82 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $194.66 | 2022-2023 | |
| Madrigal Pharmaceuticals | $181.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $177.78 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $144.80 | 2024-2025 | Zenpep, Vowst |
| Amgen INC. | $143.90 | 2021-2023 | Amjevita, Avsola |
| Janssen Scientific Affairs, LLC | $138.46 | 2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $117.04 | 2023-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $90.61 | 2021-2023 | Clenpiq |
| Ironwood Pharmaceuticals, INC | $90.59 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $77.62 | 2023 | Idacio |
| Ipsen Biopharmaceuticals, INC | $46.97 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $40.32 | 2021 | |
| Amag Pharmaceuticals, INC. | $35.04 | 2021 | |
| Braintree Laboratories, INC. | $30.35 | 2021 | |
| Gilead Sciences, INC. | $22.35 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2024 | |
| Mylan Institutional INC. | $20.51 | 2023 | |
| Sandoz INC. | $19.81 | 2023 | Hyrimoz |
| Micro-Tech Endoscopy USA, INC. | $19.32 | 2021 | |
| Ethicon US, LLC | $15.79 | 2022 | |
| Ucb, INC. | $15.30 | 2024 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narin Tipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.